NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
NEWLINK GENETICS (NLNK)
Last newlink genetics earnings: 2/28 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.linkp.com/investor-relations
Company Research
Source: GlobeNewswire
AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin, conducted in conjunction with The GOG Foundation, Inc. (GOG-3008), in patients with refractory ovarian cancer. The data were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. Abstract CT151 A Phase 2 Study of NLG207 in Combination with Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Duska L, et al. "We are encouraged by the responses observed in this Phase 2 trial of NLG207 in combination with weekly paclitaxel for patients wi
Show less
Read more
Impact Snapshot
Event Time:
NLNK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLNK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLNK alerts
High impacting NEWLINK GENETICS news events
Weekly update
A roundup of the hottest topics